Who are Peginterferon alfa-2a 40KD and Ribavirin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Peginterferon alfa-2a with Ribavirin, Peginterferon a-2a plus Ribavirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peginterferon-alfa-2a-40kd-and-ribavirin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Peginterferon alfa-2a 40KD and Ribavirin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peginterferon alfa-2a 40KD and Ribavirin (Peginterferon alfa-2a 40KD and Ribavirin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha with nucleoside analog. Area: Virology / Hepatology.

marketed Interferon alpha with nucleoside analog Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Peginterferon alfa-2a 40KD and Ribavirin (Peginterferon alfa-2a 40KD and Ribavirin) — NORDynamIC Study Group. Peginterferon alfa-2a activates interferon-alpha receptors to enhance antiviral immunity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Peginterferon alfa-2a 40KD and Ribavirin TARGET	Peginterferon alfa-2a 40KD and Ribavirin	NORDynamIC Study Group	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Peginterferon alfa-2a with Ribavirin	Peginterferon alfa-2a with Ribavirin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Peginterferon a-2a plus Ribavirin	Peginterferon a-2a plus Ribavirin	Hepatitis Resource Network	phase 3	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha with nucleoside analog class)

Hepatitis Resource Network · 1 drug in this class
NORDynamIC Study Group · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peginterferon alfa-2a 40KD and Ribavirin — Competitive Intelligence Brief. https://druglandscape.com/ci/peginterferon-alfa-2a-40kd-and-ribavirin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab